

Q1 2025 Results

Conference call and webcast for investors and analysts

29 April 2025

Forward-looking statements

This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data and AI in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet our sustainability targets, regulatory requirements and stakeholder expectations with respect to the environment; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property risks related to the Group's products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of geopolitical and/or macroeconomic volatility disrupting the operation of our global business; the risk of failure in internal control, financial reporting or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; the risk of foreign exchange rate movements impacting our financial condition or results of operations; and the impact that global and/or geopolitical events may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.

Q1 2025 Results

Conference call agenda

CEO Opening Remarks	**Pascal Soriot** Chief Executive Officer	
Financial Results	**Aradhana Sarin** Chief Financial Officer	
Oncology Haematology	**Dave Fredrickson** EVP, Oncology Haematology Business	**Susan Galbraith** EVP, Oncology Haematology R&D
BioPharmaceuticals	**Ruud Dobber** EVP, BioPharmaceuticals Business	**Sharon Barr** EVP, BioPharmaceuticals R&D
Rare Disease	**Marc Dunoyer** Chief Executive Officer, Alexion	
CEO Closing Remarks, Q&A	**Pascal Soriot** Chief Executive Officer	





CEO Opening Remarks

Pascal Soriot

CHIEF EXECUTIVE OFFICER

Strong commercial and pipeline delivery in Q1 2025

Sustained commercial momentum

+10% Total Revenue[1]

+21% Core EPS[1]

13 new approvals in key regions[2,3]

Continued pipeline delivery

5 positive Phase III readouts

Key indication expansion *Imfinzi* in GC/GEJC and *Enhertu* in breast, gastric[3]

9 NMEs delivered toward ambition of 20 by 2030 with approval of ***Beyonttra*** (acoramidis)[4]

All growth rates at CER. 1. Growth rates relative to Q1 2024 performance. 2. Key regions – US, EU, Japan, China. 3. Since Q4/FY 2024 results. 4. Alexion, AstraZeneca Rare Disease has rights to *Beyonttra* in Japan. Collaboration partners: Daiichi Sankyo (*Enhertu*).
Appendix: Glossary.

Q1 2025 – benefit from broad-based global business

Broad-based, diverse source of Total Revenue

Q1 2025 | % Total Revenue by therapy area



Q1 2025 | % Total Revenue by geography



Strength across therapy areas

Q1 2025 | Total Revenue ($m)



Growth across geographies

Q1 2025 | Total Revenue ($m)



All growth rates at CER.
Appendix: Glossary.

Investing in transformative technologies and global R&D footprint to support long-term growth ambitions

Value-enhancing business development in Q1 2025

In-vivo cell therapy

- Proposed acquisition of EsoBiotec[1]
- "Off-the-shelf" cell therapy platform

Novel modalities

- Multi-specific biologics with Harbour BioMed
- Macro-cyclic peptides with Syneron

Innovative delivery

- Exclusive license for ALT-B4 from Alteogen
- Subcutaneous formulations of multiple oncology assets

Cambridge, UK

Gothenburg, Sweden

Gaithersburg, US

Boston, US – Kendall Sq.

Shanghai, China

Beijing, China

Global presence with six strategic R&D centres

1. Proposed EsoBiotec acquisition expected to close in the second quarter of 2025, subject to customary closing conditions and regulatory clearances.
Appendix: Glossary.

A growing broad-based global footprint

Resilient, dual-source supply chain with investment in transformative technologies

31 production facilities

Key regions supplied by local manufacturing

11 US sites

Vast majority of products sold in US are manufactured in US



Financial Results

Aradhana Sarin

CHIEF FINANCIAL OFFICER

Q1 2025 – Reported profit and loss

	Q1 2025 $m	CER change %	% Total Revenue
- Product Sales	*12,875*	*9*	*95*
- Alliance Revenue	*639*	*42*	*5*
Product Revenue	**13,514**	**10**	**99**
- Collaboration Revenue	*74*	*64*	*1*
Total Revenue	**13,588**	**10**	**100**
Gross Margin	*84%*	-	
- R&D expense	(3,159)	15	23
- SG&A expense	(4,492)	3	33
Total operating expense[1]	(7,786)	7	57
Other operating income and expense	113	71	1
Operating profit	3,674	17	27
Tax rate	14%		
Reported EPS	**$1.88**	**32**	

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Absolute values at actual exchange rates; changes at CER.
1. Total operating expense includes distribution, R&D and SG&A expenses.
Appendix: Glossary.

Q1 2025 – Core profit and loss

	Q1 2025 $m	CER change %	% Total Revenue
- Product Sales	*12,875*	*9*	*95*
- Alliance Revenue	*639*	*42*	*5*
Product Revenue	**13,514**	**10**	**99**
- Collaboration Revenue	*74*	*64*	*1*
Total Revenue	**13,588**	**10**	**100**
Gross Margin	*84%*	-	
- R&D expense	(3,088)	16	23
- SG&A expense	(3,457)	4	25
Total operating expense[1]	(6,677)	9	49
Other operating income and expense	115	78	1
Operating profit	4,803	12	35
Tax rate	16%		
Core EPS	**$2.49**	**21**	

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Absolute values at actual exchange rates; changes at CER.
1. Total operating expense includes distribution, R&D and SG&A expenses.
Appendix: Glossary.

FY 2025 guidance reiterated

Net cash inflow from operating activities increased by 49% in Q1 2025

Net debt/Adjusted EBITDA 1.5x



FY 2025 guidance (CER)

Total Revenue
anticipated to increase by a **high single-digit** percentage

Core EPS
anticipated to increase by a **low double-digit** percentage

- Core tax rate expected to be between 18-22%
- Anticipated FX impact – low single-digit adverse impact on Total Revenue and Core EPS[5]

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 1. Capital expenditure on tangible assets and software-related intangible assets. 2. Comprises purchase and disposal of intangible assets (excluding software-related assets, including AZ Forest), movement in profit participation liability, purchase and disposal of non-current asset investments, payments to associates and joint ventures, disposal of investments in associates and joint ventures, acquisitions of subsidiaries, net of acquired net debt and payment of contingent consideration on business combinations. The Company uses Debt issuance to finance new Business Development opportunities. 3. Comprises mainly Own shares purchased by Employee Benefit Trust. 4. Rolling 12m EBITDA. AstraZeneca credit ratings: Moody's: short-term rating P-1, long-term rating A1, outlook stable. S&P Global Ratings: short-term rating A-1, long-term rating A+, outlook stable. 5. If foreign exchange rates for April 2025 to December 2025 were to remain at the average rates seen in March 2025. Appendix: Glossary.



Oncology

Dave Fredrickson
ONCOLOGY HAEMATOLOGY BUSINESS

Susan Galbraith
ONCOLOGY HAEMATOLOGY R&D

Oncology – Q1 2025

Strong demand across key regions, partly offset by oral oncolytics Part D redesign in US



Q1 2025: key dynamics

- ***Tagrisso*** +8%, increasing demand across indications, strong LAURA launch uptake
- ***Calquence*** +8%, continued BTKi leadership in CLL across major markets
- ***Lynparza* PR** +5%, sustained PARPi leadership
- ***Truqap*** $132m, market leadership in 2L biomarker-altered, partly impacted by one-time blister pack destocking in US
- ***Imfinzi*** +16%, strong demand growth, continued JP repricing impact
- ***Imjudo*** +33%, durable HIMALAYA demand across major markets
- ***Enhertu*** +34%, strong demand in CN post-NRDL inclusion, DESTINY-Breast06 launch
- ***Datroway*** $4m, positive early launch signals in HR+/HER2- breast

- **Key regulatory approvals**: US (*Imfinzi* NIAGARA), EU (*Imfinzi* ADRIATIC, *Enhertu* DESTINY-Breast06, *Imfinzi* AEGEAN)

Collaboration partners: Daiichi Sankyo (*Enhertu*, *Datroway*), Merck & Co., Inc. (*Lynparza*). 1. Others is inclusive of *Datroway*.
Appendix: Glossary.

Oncology – strong catalyst flow in Q1 2025

Positive key Phase III readouts reinforce leadership in breast and GI cancers

ASCO plenary

camizestrant

SERENA-6

First positive oral SERD Phase III in 1L

AI + CDK4/6i switch to cami + CDK4/6i
1L *ESR1*m HR+/HER2- mBC

- Highly significant and clinically meaningful PFS improvement
- Trend in PFS2 improvement

~10k eligible patients across G7

ASCO plenary

IMFINZI® durvalumab

MATTERHORN

Builds on AEGEAN and NIAGARA perioperative success

+ FLOT
perioperative gastric / GEJ cancer

- Significant and clinically meaningful EFS improvement
- Strong trend to OS improvement

~43k eligible patients across G7

ENHERTU® trastuzumab deruxtecan

DESTINY-Breast09

Moves *Enhertu* earlier in HER2+ mBC

+ pertuzumab
1L HER2+ mBC

- Highly significant and clinically meaningful PFS improvement
- Early trend to OS improvement

~23k eligible patients across G7

US Breakthrough Device Designation granted for TROP2-NMR companion diagnostic[1] in 2L *Datroway* TROPION-Lung17 trial

1. Co-developed with Roche Tissue Diagnostics. Collaboration partners: Daiichi Sankyo (*Enhertu*, *Datroway*).
Appendix: Glossary.

Oncology – advancing transformative technologies

Progress with in-house ADCs at Society of Gynecologic Oncology 2025

Encouraging puxitatug samrotecan Phase I/IIa data in endometrial cancer



- Promising ORR 34.6-38.5%
- Preliminary 7.0 months mPFS
- No TRAEs leading to discontinuation
- Low rates of haematologic toxicity

Initiating Phase III in endometrial cancer in 2025

AZD0901	Cldn18.2	Phase III
P-Sam	B7H4	Phase I/II → III
AZD5335	FRα	Phase I/II
AZD0305	GPRC5D	Phase I/II
AZD9829	CD123	Phase I/II
AZD9592	EGFR/cMET	Phase I

Gaillard S et al. Abstract 933087 presented at 2025 SGO Annual Meeting on Women's Cancer 2025.
Appendix: Glossary.



BioPharmaceuticals

Ruud Dobber
BioPharmaceuticals Business

Sharon Barr
BioPharmaceuticals R&D

BioPharmaceuticals – Q1 2025

Total Revenue $5.6bn, +12%, strong demand growth in expanding classes of medicines

CVRM

Q1 2025 $3.3bn, +13%



R&I

Q1 2025 $2.1bn, +13%



Q1 2025: key dynamics

- ***Farxiga*** +17%, global demand growth mainly driven by CKD and HF
- ***Lokelma*** +38%, market leader in growing class
- ***Brilinta*** (4%), generic competition ex-US
- ***Fasenra*** +19%, sustained IL-5 leadership and EGPA launch
- ***Tezspire*** +85%, continued launch momentum
- ***Breztri*** +39%, fastest growing medicine in expanding FDC triple class
- ***Saphnelo*** +51%, increasing penetration in i.v. segment
- **V&I** (1%), ***Beyfortus*** >2x Total Revenue

Key regulatory approvals:

EU (*Wainzua* NEURO-TTRansform)

Appendix: Glossary.

BioPharmaceuticals – potential best in class oral PCSK9 to address high unmet need in dyslipidaemia

AZD0780 (oPCSK9) Phase IIb PURSUIT met primary endpoint[1,2]

≥50% LDL-C reduction
at 12 weeks[3]

84% of patients
met AHA/ACC guideline-recommended LDL-C target

Oral small molecule
favourable tolerability, no food effect or fasting requirement



$5bn+ PYR[5] with oral AZD0780 add-on and combination opportunities

Progressing into three Phase IIIs

AZURE-LDL	**LDL-C reduction**
AZURE-HeFH	**Heterozygous familial hypercholesterolemia** (HeFH)
AZURE-Outcomes	**Cardiovascular outcomes**

1.. Koren M et al. Abstract featured in Clinical Research V | Session 113 at American College of Cardiology Annual Scientific Session 2025. 2. Koren MJ et al. J Am Coll Cardiol. 2025 Mar 27:S0735-1097(25)05907-8. 3. With once-daily AZD0780 (30mg) taken in addition to standard-of-care statins, LDL-C reduction 95% CI: -59.0%, -42.4%, p<0.001.
Appendix: Glossary.

Rare Disease

Marc Dunoyer

Chief Executive officer, Alexion

Rare Disease – Q1 2025

Total Revenue $2bn, confidence in future growth despite certain headwinds

Rare Disease

Q1 2025 $2bn, +0%



Q1 2025: key dynamics

C5 Franchise

- ***Ultomiris*** +25%, demand growth across indications, offset by some competitive pressure in gMG and PNH and Part D redesign in US
- ***Soliris*** (38%), continued successful conversion to *Ultomiris,* additional impact from biosimilars in EU and unfavourable order timing in certain tender markets

Beyond Complement – market expansion and increased demand

- ***Strensiq*** +14%, continued global demand, partially offset by Part D redesign in US
- ***Koselugo*** +8%, continued global demand, partially offset by unfavourable order timing in certain tender markets

- **Key regulatory approvals**: JP (*Beyonttra*[1] ATTR-CM), CN (*Ultomiris* gMG)

All growth rates at CER. 1. Formerly acoramidis. Collaboration partner: Merck & Co., Inc. (*Koselugo*).
Appendix: Glossary.

Rare Disease – advancing *Ultomiris* in rare indications

Expanding into rare haematology and renal diseases

Potential blockbuster opportunity for *Ultomiris* in HSCT-TMA across paeds and adults

TMA-314

Phase III demonstrated benefit in paediatric patients

Clinically meaningful improvements

- Platelets
- LDH
- Urinary protein/ creatinine ratio
- Overall survival

FDA BTD

TMA-313

Ongoing Phase III in adult and adolescent patients

Data readout | H2 2025

~50k HSCT procedures per year[1]

Advancing ambition in rare renal diseases

pre-transplant	post-transplant
aHUS Launched	**DGF** AWAKE | Initiating
CSA-AKI ARTEMIS | 2026	
IgAN ICAN | >2026	

Ongoing or initiating Phase III *Ultomiris* trials

1. Epidemiology reflects addressable patients across US, Germany, France, UK, Italy, Spain, Japan and Canada.
Appendix: Glossary.



CEO Closing Remarks

Pascal Soriot

CHIEF EXECUTIVE OFFICER

2025 key Phase III readouts represent >$10bn opportunity[1]

	H1 2025	H2 2025
First Phase III data for 7 NMEs	**SERENA-6** camizestrant — 1L *ESR1*m HR+/HER2- breast cancer **CALYPSO** eneboparatide — hypoparathyroidism	**CAEL-101/2** anselamimab — light chain amyloidosis **BaxHTN** baxdrostat — uncontrolled or resistant hypertension **LATIFY** ceralasertib — Post-IO NSCLC **HICKORY/CHESTNUT** efzimfotase alfa — HPP **ALXN1720-MG-301** gefurulimab — gMG
Key indication expansion opportunities	**DESTINY-Breast09** *Enhertu* — 1L HER2+ breast cancer **DESTINY-Breast11** *Enhertu* — early-stage HER2+ breast **TROPION-Breast02** *Datroway* — 1L TNBC **KALOS/LOGOS** *Breztri* — uncontrolled asthma **POTOMAC** *Imfinzi* — NMIBC	**AVANZAR** *Datroway + Imfinzi* — 1L NSCLC **RESOLUTE** *Fasenra* — COPD **TMA-313** *Ultomiris* — adult HSCT-TMA **VOLGA** *Imfinzi* — cis-ineligible/refuse MIBC **DESTINY-Breast05** *Enhertu* — early-stage HER2+ breast

1. risk-adjusted peak year revenue. Collaboration partner: Daiichi Sankyo (*Enhertu, Datroway*).
Appendix: Glossary.

On track to deliver on 2030 ambitions supported by strong growth and pipeline momentum

Ambition to deliver **$80bn in Total Revenue by 2030**[1]

Strong growth in 2025 with global medicines demand substantially offsetting anticipated headwinds

On track to deliver **mid-30s% Core operating margin by 2026**

Growth in SG&A slower than Total Revenue

R&D to remain low 20%s of Total Revenue

Ambition to deliver **at least 20 NMEs by 2030**

9 NMEs launched to date

The Financial Ambition Statements in this presentation are based on Q1 2024 exchange rates.
1. 2030 Total Revenue ambition is risk-adjusted and not dependent upon future M&A.
Appendix: Glossary.



Q&A Session

Pascal Soriot
CHIEF EXECUTIVE OFFICER

Aradhana Sarin
CHIEF FINANCIAL OFFICER

Marc Dunoyer
CHIEF EXECUTIVE OFFICER, ALEXION

Susan Galbraith
EVP, ONCOLOGY HAEMATOLOGY R&D

Dave Fredrickson
EVP, ONCOLOGY HAEMATOLOGY BUSINESS

Sharon Barr
EVP, BIOPHARMACEUTICALS R&D

Ruud Dobber
EVP, BIOPHARMACEUTICALS BUSINESS

Iskra Reic
EVP, INTERNATIONAL



Appendix

Appendix – AstraZeneca P&L reference table

P&L line-item definitions

	P&L line-item definition
Product Sales	• Recognises sales from territories where Group has lead commercialisation • Recognises supply of *Beyfortus* to Sanofi
Alliance Revenue	• Alliance Revenue comprises income arising from the ongoing operation of collaborative arrangements related to sales made by collaboration partners, where AstraZeneca is entitled to a share of gross profits, share of revenues or royalties, which are recurring in nature while the collaboration agreement remains in place[1]
Product Revenue	• The sum of Product Sales and Alliance Revenue
Collaboration Revenue	• Recognises any development or sales-based milestone received on partnered medicines as well as any upfront payments associated with business development where AstraZeneca retains a significant ongoing economic interest in the product
Total Revenue	• Sum of Product Sales, Alliance Revenue and Collaboration Revenue
Gross Margin	• Calculated by dividing Gross Profit by Total Revenue
Other operating income & expense	• Other operating income and expense is generated from activities outside of the Group's normal course of business, which includes Other income from divestments of or full out-license of assets and businesses including royalties and milestones where the Group does not retain a significant continued interest
Core Operating margin	• Defined as Core Operating profit as a percentage of Total Revenue

1. Partnered medicines include: *Enhertu*, *Lynparza, Datroway*, *Beyfortus*, *Tezspire*. Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges.

Appendix: Glossary.

AstraZeneca in Lung Cancer (NSCLC)

Overview of commercial portfolio and pivotal trials



established SoC
launched indication

Lung Cancer map reflects ongoing active Phase III trials. Collaboration partners: Daiichi Sankyo (*Enhertu*, *Datroway*), Compugen (rilvegostomig).
Appendix: Glossary.

AstraZeneca in Breast Cancer

Overview of commercial portfolio and pivotal trials



All numbers are approximate. Illustrative settings and populations, not to scale.
Collaboration partners: Daiichi Sankyo (*Enhertu*, *Datroway*), Merck & Co., Inc. (*Lynparza*).
Appendix: Glossary.

established SoC
launched indication

Appendix – Significant progress with transformative technologies to drive 2030+ growth

Weight management and risk factors	ADCs and Radioconjugates	Next-gen IO bispecifics	Cell therapy and T-cell engagers	Gene therapy and gene editing
Establish and lead in new weight management paradigm	Replace systemic chemotherapy and radiotherapy	Replace existing PD-1/ PD-L1 inhibitors	Develop scalable cell therapies and T-cell engagers across therapy areas	Make cure possible for a range of rare diseases
Multiple Phase II dose optimisation trials ongoing **AZD5004 (oGLP-1)** **AZD6234 (LAA)**	*Six ADCs in clinical development, including:* **AZD0901 (CLDN18.2) in Phase III** **FPI-2265 Phase II initiated in pre-treated PSMA-positive mCRPC**	**9 Phase III trials with rilvegostomig and volrustomig initiated** **First ADC combination data at ASCO 2025**	**AZD0120 (BCMA/CD19) CAR-T Phase III planned in multiple myeloma** **AZD0486 (CD19/CD3) Phase III initiated in 1L FL**	*Preclinical and Phase I development ongoing across multiple platforms* **sAAVy and AAV capsid** **TALEN technology**

ADCs/RCs, next-gen IO and cell therapy/TCE progressed to Phase III

Collaboration partners: Compugen (rilvegostomig).
Appendix: Glossary.

Oncology

Tagrisso

8% growth at CER to $1,679m in Q1 2025



	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
EM	444	408	409	360	488	432	446	391	519
ERoW	202	218	198	163	182	191	186	201	175
Europe	257	284	281	299	302	327	328	344	307
US	521	581	577	597	623	658	714	767	678

Lynparza

5% growth at CER to $726m in Q1 2025

	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
EM	137	142	131	133	167	153	155	180	161
ERoW	68	77	71	65	59	66	62	66	57
Europe	178	187	178	191	191	206	214	220	196
US	268	311	322	352	288	319	347	378	312

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Collaboration partner: Merck & Co., Inc. (*Lynparza*).
Appendix: Glossary.

Oncology

Imfinzi

16% growth at CER to $1,261m in Q1 2025



	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
EM	81	101	86	87	129	117	120	113	142
ERoW	129	201	207	213	170	183	167	167	139
Europe	162	171	203	207	232	227	236	253	252
US	491	540	570	570	582	620	680	721	728

Imjudo

33% growth at CER to $80m in Q1 2025



	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
EM	0	1	1	3	4	4	4	5	5
ERoW	4	22	14	12	11	13	12	13	11
Europe	1	5	5	5	8	8	10	10	11
US	32	36	40	38	39	49	46	45	53

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Appendix: Glossary.

Oncology

Calquence

8% growth at CER to $762m in Q1 2025



	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
EM	18	24	28	29	39	36	41	37	54
ERoW	22	27	30	28	32	33	33	31	31
Europe	108	117	128	140	153	167	169	167	170
US	384	485	468	478	494	554	570	573	507

Enhertu

34% growth at CER to $596m in Q1 2025



	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
EM	38	69	72	74	112	112	128	125	172
ERoW	3	5	9	15	13	19	16	22	19
Europe	55	70	79	91	134	129	136	142	146
US	161	178	179	184	202	212	229	250	258

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Collaboration partner: Daiichi Sankyo (*Enhertu*).
Appendix: Glossary.

BioPharmaceuticals: Cardiovascular, Renal & Metabolism

Farxiga

16% growth at CER to $2,058m in Q1 2025



	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
EM	498	578	577	559	711	763	750	628	871
ERoW	114	135	104	72	109	104	108	103	121
Europe	393	456	506	525	553	680	670	731	683
US	296	339	366	451	473	394	411	472	383

Brilinta

4% decrease at CER to $305m in Q1 2025



	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
EM	82	79	64	61	88	78	66	62	74
ERoW	6	6	6	6	5	4	5	6	3
Europe	67	68	68	68	67	69	67	65	55
US	179	178	193	194	163	191	189	208	173

Lokelma

38% growth at CER to $153m in Q1 2025



	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
EM	11	13	13	13	21	21	26	18	30
ERoW	20	24	22	24	23	28	26	31	28
Europe	11	14	16	17	18	23	25	26	26
US	56	49	51	58	52	64	66	75	69

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Appendix: Glossary.

BioPharmaceuticals: Respiratory & Immunology

Fasenra

19% growth at CER to $418m in Q1 2025



	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
EM	14	14	19	16	22	19	27	23	27
ERoW	35	36	35	36	33	37	36	39	39
Europe	88	89	86	93	93	99	102	110	103
US	201	267	249	275	210	268	271	299	249

Tezspire

85% growth at CER to $217m in Q1 2025



	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
EM	0	0	0	1	2	3	3	4	7
ERoW	4	8	10	14	14	19	22	25	23
Europe	7	11	11	17	27	35	43	51	57
US	43	62	74	83	77	104	123	133	130

Saphnelo

51% growth at CER to $136m in Q1 2025



	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
EM	0	1	0	1	1	1	3	2	3
ERoW	2	2	3	3	3	4	4	5	4
Europe	1	1	2	3	4	6	7	9	9
US	44	64	71	82	83	101	110	131	120

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Collaboration partner: Amgen (*Tezspire*).
Appendix: Glossary.

BioPharmaceuticals: Respiratory & Immunology

Breztri

39% growth at CER to $300m in Q1 2025



	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
EM	38	43	42	38	70	61	68	45	90
ERoW	10	15	12	15	14	19	19	21	20
Europe	15	21	19	26	30	35	37	42	42
US	81	84	98	120	105	120	142	149	148

Symbicort

3% decrease at CER to $723m in Q1 2025



	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
EM	229	177	195	153	253	197	203	153	232
ERoW	79	86	81	88	75	83	83	88	77
Europe	147	137	123	142	142	143	130	144	135
US	233	200	156	137	299	299	289	299	279

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Appendix: Glossary.

Rare Disease

Ultomiris

25% growth at CER to $1,050m in Q1 2025



	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
EM	13	17	17	24	32	35	26	49	52
ERoW	98	110	131	138	143	152	170	173	166
Europe	159	152	184	173	202	209	238	235	228
US	381	434	445	490	482	550	597	632	604

Strensiq

14% growth at CER to $352m in Q1 2025



	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
EM	15	9	5	11	21	10	8	15	34
ERoW	21	22	21	22	22	23	24	27	26
Europe	21	21	22	25	24	24	25	26	26
US	205	248	237	247	246	283	286	352	266

Koselugo

8% growth at CER to $138m in Q1 2025



	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
EM	24	14	11	10	59	24	25	69	40
ERoW	3	6	7	9	9	9	10	11	11
Europe	11	12	15	15	18	26	29	29	34
US	41	48	54	51	46	55	55	56	53

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Appendix: Glossary.

Glossary

1L, 2L, 3L	first-, second-, third-line
AAV	adeno-associated virus
ACC	American College of Cardiology
ADC	antibody-drug conjugate
AHA	American Heart Association
aHUS	atypical haemolytic uraemic syndrome
AI	aromatase inhibitor
AKT1	AKT serine/threonine kinase 1
B7H4	B7 homolog 4
BCMA	B-cell maturation antigen
BTKi	Bruton's tyrosine kinase
CAR-T	chimeric antigen receptor T-cells
CD123	interleukin-3 receptor alpha chain
CD19	cluster of differentiation 19
CD3	cluster of differentiation 3
CDK4/6i	cyclin-dependent kinase 4/6 inhibitor
CER	constant exchange rates
CFO	net cash inflow from operating activities
cis	cisplatin
CKD	chronic kidney disease
CLDN18.2	Claudin-18.2
CLL	chronic lymphocytic leukaemia
cMET	c-mesenchymal epithelial transition factor
CN	China
COPD	chronic obstructive pulmonary disease
CR	Collaboration Revenue
CRT	chemoradiotherapy
CSA-AKI	cardiac surgery-associated acute kidney injury
CTx	chemotherapy
CVRM	Cardiovascular, Renal and Metabolism
Dato-DXd	Datroway
DGF	delayed graft function
EBITDA	earnings before interest, tax, depreciation and amortisation
EGFR	epidermal growth factor receptor
EGFRm	epidermal growth factor receptor-mutant
EPS	earnings per share
ERoW	Established Rest of World
ESR1m	estrogen receptor alpha-mutated
EU	Europe
FDC	fixed-dose combination
FL	follicular lymphoma
FLOT	luorouracil, leucovorin, oxaliplatin and docetaxel
FRα	folate receptor alpha
FX	foreign exchange
G7	US, Japan, EU5
gBRCAm	germline BRCA-mutated breast cancer
GC	gastric cancer
GEJ	gastroesophageal junction
GEJC	gastroesophageal junction cancer
GI	gastrointestinal
gMG	generalised myasthenia gravis
GPRC5D	G protein-coupled receptor class C group 5 member D
HeFH	heterozygous familial hypercholesterolemia
HER2-	human epidermal growth factor receptor 2
HER2+	human epidermal growth factor receptor 2-positive
HER2-low	human epidermal growth factor receptor 2-low
HER2-ultralow	human epidermal growth factor receptor 2-ultralow
HF	heart failure
HPP	hypophosphatasia
HR+	hormone receptor positive
HSCT	hematopoietic stem cell transplantation
HSCT-TMA	hematopoietic stem cell transplantation-associated thrombotic microangiopathy
i.v.	intravenous
IgAN	IgA nephropathy
IL-5	interleukin-5
IO	immuno-oncology
JP	Japan
LAA	long-acting amylin
LDH	lactate dehydrogenase
LDL-C	low-density lipoprotein cholesterol
mBC	metastatic breast cancer
mCRPC	metastatic castration-resistant prostate cancer
MIBC	muscle-invasive bladder cancer
mPFS	median progression-free survival
NME	new molecular entity
NMIBC	non-muscle invasive bladder cancer
NMR	normalised membrane ratio
NRDL	national reimbursement drug list
NSCLC	non-small cell lung cancer
NSQ	non-squamous
NST	neoadjuvant systemic treatment
oGLP-1	oral glucagon-like peptide-1
oPCSK9	oral protein convertase subtilisin/kexin type 9
ORR	overall response rate
OS	overall survival
P&L	Profit & Loss
PALB2m	partner and localizer of BRCA2
PARPi	poly-ADP ribose polymerase inhibitor
PCSK9	protein convertase subtilisin/kexin type 9
PD-1	programmed cell death protein-1
PDL1	programmed death-ligand 1
PD-L1	programmed cell death ligand 1
PFS	progression free survival
PIK3CA	phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit
PNH	paroxysmal nocturnal haemoglobinuria
PS	Product Sales
PSMA	prostate-specific membrane antigen
PTEN	phosphatase and TENsin homolog deleted on chromosome 10
PYR	Peak-Year Revenue
R&D	Research & Development
R&I	Respiratory & Immunology
RC	radioconjugate
SERD	selective estrogen receptor degrader
SG&A	Selling, General & Administrative
SoC	standard-of-care
SQ	squamous
Stg.	stage
tBRCAm	tumor BRCA mutation
TCE	T-cell engager
THP	docetaxel, trastuzumab and pertuzumab
TL07	TROPION-Lung07
TL08	TROPION-Lung08
TNBC	triple negative breast cancer
TRAE	treatment-related adverse event
TROP2	trophoblast cell surface antigen 2
UK	United Kingdom
US	United States
V&I	Vaccines & Immune Therapies

AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK
+44(0)203 749 5000
www.astrazeneca.com